TD Cowen Maintains ATAI Life Sciences(ATAI.US) With Buy Rating
TD Cowen analyst Ritu Baral maintains $ATAI Life Sciences(ATAI.US)$ with a buy rating.According to TipRanks data, the analyst has a success rate of 44.1% and a total average return of 7.4% over the pa
Atai Life Sciences CEO Talks Successful Phase 1 Trial of IV Psilocin Formulation – ICYMI | NASDAQ:ATAI, ETR:9VC
Atai Life Sciences to Participate in the H.C. Wainwright 5th Annual Neuro Perspectives Conference
NEW YORK and BERLIN, June 26, 2024 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ:ATAI) ("atai" or "Company"), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders,
Atai Life Sciences Co-CEO Says Initial Results From ELE-101 Show Promise in Treating Depression | NASDAQ:ATAI, ETR:9VC
Cantor Fitzgerald Reiterates Overweight on ATAI Life Sciences
Cantor Fitzgerald analyst Charles Duncan reiterates ATAI Life Sciences (NASDAQ:ATAI) with a Overweight.
ATAI Life Sciences Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 06/21/2024 — Cantor Fitzgerald Reiterates → Overweight 05/17/2024 1049.43% HC Wainwright & Co. $15 → $15
Atai Life Sciences Announces Update on Beckley Psytech's Phase 1/2a Trial of ELE-101 (IV Psilocin) for Major Depressive Disorder, With Initial Results From Phase 1 and First Patients Dosed in Phase 2a
ELE-101 is a patent-protected, synthetic formulation of psilocin, designed to offer the therapeutic benefits of psilocybin in a more consistent, controllable, and shorter treatment paradigm of approximately two hours.The
Atai Life Sciences Optimistic as IV Psilocin Shows Promise in Treating Depression in Early Trial | NASDAQ:ATAI, ETR:9VC
Atai Life Sciences Poised for Success With Rigorous Clinical Trials | NASDAQ:ATAI, ETR:9VC
Don't Freak Out. It Isn't the End of the Line for Psychedelic Medicines. -- Barrons.com
By Josh Nathan-Kazis Turn on, tune in, drop in value. A frigid reception for one novel psychedelic treatment by a Food and Drug Administration advisory committee doesn't spell doom for all psychedel
Express News | Vir Biotech rose by 19.66%, while novavax rose by 18.07%. Terns Pharmaceuticals, protagonist therapeutics, pacific biosciences of california, adaptive biotechnologies all rose by 16.84-13.27%. Avadel Pharmaceuticals Plc. dropped 3.82% and performed third
Psychedelic Stocks Trip Up After FDA Advisors Reject MDMA For PTSD Treatment
A panel of advisors to the Food and Drug Administration (FDA) rejected MDMA as a treatment for post-traumatic stress disorder (PTSD) on Tuesday, citing a lack of evidence that the benefits would outwe
What's Going On With MindMed And Psychedelic Stocks?
Mind Medicine (MindMed) Inc. (NASDAQ:MNMD) shares are trading lower Wednesday after a Food and Drug Administration (FDA) panel rejected the approval of MDMA therapy for people with post-traumatic stre
FDA advisory group refuses MDMA marketing authorization; psychedelic concept stocks slump.
The independent advisory group of the US FDA voted against the marketing authorization application for the psychiatric drug MDMA, causing a pre-market drop for the hallucinogenic drug developer.
Psychedelic Stocks Fall as FDA Panel Rejects MDMA Therapy
FDA Advisory Panel Fails to Endorse Psychedelic MDMA Therapy for PTSD
Psychedelic Stocks Mixed as FDA Comments on MDMA Therapy
Atai Life Sciences to Participate in the Jefferies 2024 Global Healthcare Conference
NEW YORK and BERLIN, May 31, 2024 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ:ATAI) ("atai" or "Company"), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders,
ATAI Life Sciences Announces Appointment of Scott Braunstein and Laurent Fischer as Independent Directors >ATAI
ATAI Life Sciences Announces Appointment of Scott Braunstein and Laurent Fischer as Independent Directors >ATAI
Press Release: Atai Life Sciences Strengthens Board With Appointment of Two New Independent Directors
atai Life Sciences Strengthens Board with Appointment of Two New Independent Directors NEW YORK and BERLIN, May 23, 2024 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) ("atai" or "Company"), a